Analyst Insight: Many biotech firms struggle to manage the order-to-cash (O2C) cycle effectively because large contract manufacturers (CMOs) often handle physical shipping, while the firm retains ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results